Tolebrutinib (SNY) FDA Complete Response Letter in nrSPMS: Dec 23, 2025
Page updated ·next FDA decision on the calendar·Data as of Nov 19, 2026 12:24 AM ET
The FDA's own letter · Complete Response Letter, NDA 219624 (PDF), dated December 23, 2025, released under FDA's CRL transparency program. The company announced the decision on December 24, 2025; the FDA acted on December 23, 2025.
Sections the letter addresses (its own headings, read from the PDF's text layer; labeling and administrative sections omitted): Risk Evaluation and Mitigation Strategy Requirements.
✕ COMPLETE RESPONSE LETTER
Verified against: FDA action day December 23, 2025 (FDA Complete Response Letter) · Announcement December 24, 2025 · Goal date: none on record.
This page was first committed to pdufa.bio's public repository on Nov 17, 2026, 10:25 PM ET (public commit d939eae). Dates on this page are the FDA's and the sponsor's; this line is ours.
The FDA issued a Complete Response Letter for tolebrutinib in non-relapsing secondary progressive multiple sclerosis on December 23, 2025, declining to approve it in its current form. Sanofi announced it on December 24.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (7/7/25) through T+5. Run-up high $52.34 on 11/13/25, low $45.07 on 9/25/25 (T-120 to T-1). Announced 12/24/25 (FDA action 12/23/25). Historical price action, not a forecast.
Move measured on2025-12-24 close (the announcement day), against the 2025-12-23 close
Cohort decision-day move (history)1.0% median (n=828)
The FDA's Complete Response Letter for NDA 219624 is dated December 23, 2025 (FDA CRL file); in it the FDA writes that it was unable to identify a population for which the benefit could be clearly established. Sanofi announced the letter on December 24, 2025 (Sanofi's release). The review's target action date was December 28, 2025. This page replaces one dated December 28 (see /corrections).
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
FDA record of the action: the FDA issued a Complete Response Letter on December 23, 2025, per NDA 219624 CRL (FDA letter). The sponsor announced it on December 24, 2025. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.
Questions
Was tolebrutinib approved by the FDA?
Not in this review cycle. On December 23, 2025 the FDA issued a Complete Response Letter, declining to approve the application for tolebrutinib in its current form. The company announced it on December 24, 2025. A CRL is not final; the primary source is linked on this page.
Which company is behind tolebrutinib?
tolebrutinib is a Sanofi (SNY) program. The FDA decision came on December 23, 2025; the company's own announcement is linked on this page.
How did SNY stock react to the FDA decision?
SNY moved +0.1%, measured as the 2025-12-24 close (the announcement day) against the 2025-12-23 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.